Evidio Domingo-Musibay, MD

Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation

Evidio Domingo-Musibay

Contact Info

Mailing Address:
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Sarah Strommer

Administrative Phone

Administrative Email

Medical School, University of Minnesota, Minneapolis, MN

Residency, Mayo Clinic, Rochester, MN

Fellowship, Mayo Clinic, Rochester, MN


Dr. Domingo-Musibay is an Assistant Professor of Medicine in the Division of Hematology, Oncology and Transplantation at the University of Minnesota and member of the Masonic Cancer Center. My clinical and translational research efforts focus on immunologic, cellular, and viral and gene therapy treatments for solid tumors. I am particularly interested in defining optimal immunotherapy sequencing strategies and mechanisms of resistance to standard immunotherapy agents, and identification of promising in situ vaccination and adoptive cell therapy based immunotherapy treatments. My graduate and post-graduate training in virology, immunology, and hematology/oncology has equipped me to interface between basic science discovery and clinical translation of novel therapies for cancer patients.

Awards & Recognition

  • Merrill J. Egorin Workshop in Cancer Therapeutics and Drug Development, 2014
  • Cedars-Sinai Clinical and Translational Research Workshop, 2015

Professional Associations

  • Member, Society for Melanoma Research, 2016-present 
  • Member, American Association of Cancer Research, 2016-present 
  • Member, Society for Immunotherapy of Cancer, 2016-present 
  • Member, American Society of Clinical Oncology, 2013-present
  • Member, Connective Tissue Oncology Society, 2013-present
  • Member, American Society of Hematology, 2013-present


Research Summary/Interests

  • Immunotherapy
  • Adoptive cell therapy
  • Virotherapy


Clinical Interests

Dr. Domingo-Musibay has clinical interests in sarcoma, cutaneous oncology and melanoma. He has a special interest in personalized therapy approaches to cancer treatment. His research focuses on identification and translation of novel targeted therapies for cutaneous oncology patients.